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Elafin is a 6-kDa innate immune protein present at several
epithelial surfaces including the pulmonary epithelium. It is
a canonical protease inhibitor of two neutrophil serine pro-
teases wneutrophil elastase (NE) and proteinase 3x with the
capacity to covalently bind extracellular matrix proteins by
transglutamination. In addition to these properties, elafin also
possesses antimicrobial and immunomodulatory activities.
The aim of the present study was to investigate the effect of
Pseudomonas aeruginosa proteases on elafin function. We
found that P. aeruginosa PAO1-conditioned medium and two
purified Pseudomonas metalloproteases, pseudolysin (elas-
tase) and aeruginolysin (alkaline protease), are able to cleave
recombinant elafin. Pseudolysin was shown to inactivate the
anti-NE activity of elafin by cleaving its protease-binding
loop. Interestingly, antibacterial properties of elafin against
PAO1 were found to be unaffected after pseudolysin treat-
ment. In contrast to pseudolysin, aeruginolysin failed to inac-
tivate the inhibitory properties of elafin against NE.
Aeruginolysin cleaves elafin at the amino-terminal Lys6-
Gly7 peptide bond, resulting in a decreased ability to cova-
lently bind purified fibronectin following transglutaminase
activity. In conclusion, this study provides evidence that ela-
fin is susceptible to proteolytic cleavage at alternative sites
by P. aeruginosa metalloproteinases, which can affect dif-
ferent biological functions of elafin.
Present address: EA4303 ‘Immunite´ et Inflammation de l’Epithe´-a
lium Respiratoire’, IFR53, Universite´ de Reims Champagne-
Ardenne, F-51100 Reims, France.
Keywords: antimicrobials; antiproteases; cleavage;
microbial; proteases; transglutaminase.
Introduction
Elafin, also known as SKALP (Skin-derived AntiLeuko-
Protease) or ESI (Elastase-Specific Inhibitor), is a small-size
(6 kDa, 57 amino acids), cationic protease inhibitor first dis-
covered in the skin (Schalkwijk et al., 1990; Wiedow et al.,
1990) and the lung (Sallenave and Ryle, 1991). Similar to
SLPI (secretory leucoprotease inhibitor), elafin belongs to
the chelonianin family, one of the 18 families of canonical
inhibitors. Structurally, this inhibitor is a member of the WAP
(whey acidic protein) family which is characterised by the
presence of one or more domain that contains eight highly
conserved cysteine residues organised into four disulphide
bridges. Elafin is generated from a longer molecule known
as trappin-2 or pre-elafin (10 kDa) possessing, in addition to
the WAP domain, an amino-terminal cementoin domain, rich
in transglutaminase substrate motifs with the consensus
sequence GQDPVK. These sequences allow the inhibitor to
covalently bind to a number of extracellular matrix (ECM)
proteins following the catalytic action of transglutaminases
(Nara et al., 1994; Guyot et al., 2005b). The presence of
elafin in vivo indicates that the inhibitory WAP domain (ela-
fin) is released from trappin-2 by proteolytic cleavage. A
previous study showed that the mast cell protease tryptase
could be involved in this process as the enzyme is able to
generate elafin from trappin-2 (Guyot et al., 2005a). Both
elafin and trappin-2 are potent inhibitors of two neutrophil
serine proteases: neutrophil elastase (NE) and proteinase 3
(Pr3) (Ying and Simon, 1993; Zani et al., 2004). Trappin-2/
elafin is mainly produced by epithelial cells and its expres-
sion is upregulated during inflammation. IL-1b, TNF-a,
lipopolysaccharide (LPS) and NE are inflammatory media-
tors known to increase expression of the inhibitor in lung
and skin epithelial cells (Sallenave et al., 1994; Reid et al.,
1999; Pfundt et al., 2000; Bingle et al., 2001; Simpson et
al., 2001; Meyer-Hoffert et al., 2003). The inhibitory prop-
erties of trappin-2/elafin confer a protective role for this pro-
tein in shielding mucosal surfaces against excessive
neutrophil-mediated proteolysis during inflammation.
Although elafin and trappin-2 were originally identified as
antiproteases, recent studies indicate that elafin/trappin-2
possesses immunomodulatory (Henriksen et al., 2004; Butler
et al., 2006), antibacterial (Simpson et al., 1999; Baranger et
al., 2008), antifungal (Baranger et al., 2008) and antiviral
activities. Readers are directed to a recent review of the func-
tional activities of elafin/trappin-2 (Moreau et al., 2008).
The regulation of excessive proteolytic activity of neutro-
phil serine proteases during lung inflammation is crucial to
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prevent serious tissue damage. Multiple factors in the pul-
monary environment can inactivate endogenous protease
inhibitors wa-1-antitrypsin (AAT), SLPI, elafinx and affect
the local protease-antiprotease balance. Two distinct mech-
anisms are known to inactivate neutrophil serine protease
inhibitors: oxidation and proteolytic inactivation. The lung
environment during inflammation is oxidative as a result of
reactive oxygen species produced by neutrophils. AAT, SLPI
and elafin contain a methionine residue in their inhibitory
loop that can be oxidised into a methionine sulphoxide. This
modification was shown to considerably decrease the affinity
of the antiproteases for their target enzymes (Beatty et al.,
1980; Boudier and Bieth, 1994; Nobar et al., 2005). Host
and exogenous proteases can also mediate the inactivation of
inhibitors. Several matrix metalloproteases are known to
cleave and inactivate AAT (Banda et al., 1980; Michaelis et
al., 1990; Mast et al., 1991). SLPI was shown to be cleaved
and inactivated by elastolytic cysteine cathepsins B, L and S
in the epithelial lining fluid from emphysematous patients
(Taggart et al., 2001). Elafin and AAT (but not human SLPI)
are susceptible to proteolytic activity of the house dust mite
protease Der p 1 (Brown et al., 2003). We have recently
demonstrated that excessive levels of NE activity in the
Pseudomonas-infected cystic fibrosis lung can degrade and
inactivate activities associated with elafin function (Guyot et
al., 2008). Bacterial proteases can also be involved in main-
taining inflammation by breaking down the lung anti-elastase
screen. Pseudomonas aeruginosa, an opportunistic pathogen
involved in several severe human infections, produces metal-
loproteases able to cleave a large variety of substrates includ-
ing ECM proteins, cytokines, chemokines, immunoglobulins,
complement components, antimicrobial peptides/proteins and
protease inhibitors. Among the metalloproteases secreted by
P. aeruginosa, pseudolysin (also called Pseudomonas elas-
tase or LasB) has previously been reported to cleave and
inactivate AAT and SLPI (Morihara et al., 1979; Johnson et
al., 1982). To date, the proteolytic inactivation of elafin by
bacterial proteases remains poorly studied. Only one recent
study reports the cleavage of elafin within its protease-bind-
ing loop by the cysteinyl protease RgpB from Porphyro-
monas gingivalis (Kantyka et al., 2009). Given the virulence
of P. aeruginosa and the vulnerability of the pulmonary anti-
elastase screen to proteolytic inactivation, the aim of the
present study was to evaluate the effect of Pseudomonas pro-
teases on elafin.
Results
Effect of PAO1-conditioned medium on the integrity
of elafin, SLPI and AAT
PAO1-conditioned medium was used as a complex medium
to evaluate the effect of proteases secreted by P. aeruginosa
on elafin. The elastase inhibitor was incubated with the
PAO1-conditioned medium and analysed by Western blot
using a biotinylated anti-elafin antibody. As shown in Figure
1A, elafin was quickly cleaved following 1-h exposure to the
Pseudomonas medium. The class of protease(s) involved in
the degradation of elafin was investigated by pretreating the
medium with protease inhibitors. Figure 1B shows that only
metalloprotease inhibitors (EDTA, GM6001 and phospho-
ramidon) could prevent the cleavage of elafin by PAO1-con-
ditioned medium. Interestingly, phosphoramidon, an inhibitor
of the Pseudomonas metalloprotease pseudolysin, was able
to prevent elafin degradation after 2 h incubation but not
24 h. These results indicate that one or several Pseudomonas
metalloprotease(s) including pseudolysin are involved in this
process. The effect of PAO1-conditioned medium on SLPI
and AAT was determined as positive controls as both inhib-
itors were previously shown to be cleaved by pseudolysin.
As demonstrated in Figure 1C and D, SLPI and AAT were
cleaved after 24 h incubation with Pseudomonas-conditioned
medium. Interestingly, none of the individual non-specific
inhibitors used in the study could prevent the cleavage of
these antiproteases. However, the use of the serine protease
inhibitor Pefabloc combined to the metalloprotease inhibitor
EDTA was able to protect both SLPI and AAT against pro-
teolysis (Figure 1C, D).
Effect of PAO1-conditioned medium on the
antiprotease activities of elafin
As PAO1-conditioned medium was capable of cleaving ela-
fin, we investigated whether this cleavage had any effects on
the ability of elafin to inhibit NE using the chromogenic
substrate N-(methoxysuccinyl)-Ala-Ala-Pro-Val-para-nitroa-
nilide (MeOSuc-AAPV-pNA). Full-length elafin was approx-
imately 100% inhibitory towards NE but its efficacy
decreased to approximately 15% inhibition of NE activity
after 1-h exposure to PAO1-conditioned medium (Figure 2).
This decrease in inhibition was completely prevented by pre-
treating the medium with EDTA and phosphoramidon. Our
result indicates that Pseudomonas metalloprotease(s) play a
crucial role in cleaving and inactivating elafin and its ability
to inhibit its cognate protease NE.
Effect of purified Pseudomonas metalloproteases
on elafin integrity and antiprotease activity
Given the previous findings, purified Pseudomonas metal-
loproteases were investigated for their ability to cleave and
inactivate elafin. Dose-response incubations of pseudolysin,
staphylolysin (LasA) or aeruginolysin (Pseudomonas alka-
line protease) were carried out for 2 h at 378C and analysed
by SDS-PAGE. As shown in Figure 3, recombinant elafin is
cleaved by 10 nM pseudolysin (Figure 3A) and by 400 nM
aeruginolysin (Figure 3C). In contrast, staphylolysin does not
cleave elafin even at the highest concentration tested
(10 mM; Figure 3B).
The effect of proteolytic cleavage on the inhibitory activ-
ity of elafin was investigated by measuring the anti-NE activ-
ity of elafin preincubated with various concentrations of
pseudolysin (5–500 nM) and aeruginolysin (200–2000 nM)
for various times (0, 1, 2 and 6 h) at 378C. As shown in
Figure 4A (i), pseudolysin gradually inactivated the antipro-
tease activity of elafin as a function of the enzyme concen-
tration and the incubation time. Although the inhibition of
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Article in press - uncorrected proof
Figure 1 Effect of Pseudomonas aeruginosa (PAO1)-conditioned medium on the integrity of elastase inhibitors elafin, SLPI and AAT.
In total, 8.5=10-7 M of elastase inhibitors (elafin, SLPI and AAT) were incubated with 10 ml PAO1-conditioned medium at 378C and
analysed by Western blotting. (A) Time-course incubation of recombinant elafin with PAO1-conditioned medium for 0, 1, 2, 6 and 24 h.
Incubation products were analysed by Western blotting under reducing (upper panel) and non-reducing (lower panel) conditions. Arrowheads
indicate cleavage products of elafin. (B) Identification of the Pseudomonas proteases involved in elafin cleavage. PAO1-conditioned medium
was preincubated with the indicated protease inhibitors (right panels) and mixed with recombinant elafin for 2 h (upper panels) and 24 h
(lower panels). Elafin alone, PAO1-conditioned medium incubated in absence (Con) or presence of elafin (qElafin) are indicated in the left
panels. Effect of PAO1-conditioned medium on (C) SLPI and (D) AAT integrity, and identification of the Pseudomonas proteases involved
in their cleavage are shown. PAO1-conditioned medium was preincubated with the indicated protease inhibitors (middle panels) before
incubation with SLPI and AAT for 24 h. SLPI or AAT alone, PAO1-conditioned medium incubated in absence (Con) or presence of SLPI
(qSLPI) or AAT (qAAT) are indicated in the left and right panels.
NE by elafin was approximately 94–96% at the initial time
of incubation and approximately 92% after 6 h at 378C, we
found that both 50 and 500 nM pseudolysin led to the rapid
inactivation of elafin as NE inhibition was reduced to 21%
and 15% after 2 h of incubation, respectively, and still con-
tinued to decrease to 5–8% inhibition after 6 h. Preincuba-
tion of 500 nM pseudolysin with EDTA completely inhibited
pseudolysin-mediated inactivation of elafin as 95% of NE
inhibition by elafin remained after 6 h at 378C. Western blot
analysis of samples with 50 nM of pseudolysin was per-
formed to correlate the loss of activity with proteolytic cleav-
age. As shown in Figure 4A (ii), the majority of elafin was
cleaved within 1 h of incubation. A fragment with an appar-
ent mass slightly lower to that of native elafin was detectable
under non-reducing conditions. Further cleavage of this frag-
ment was detected with prolonged exposure as the amount
of this fragment decreased from 1 h to 6 h incubation, where-
as another fragment with a lower apparent mass was gener-
ated during the same period of time. Taken together, these
results suggest that 50 nM pseudolysin rapidly cleaved elafin
in such a way as to inactivate its anti-NE activity.
In contrast to pseudolysin, aeruginolysin did not inactivate
the antiprotease activity of elafin, despite its ability to cleave
the protein. Indeed, Figure 4B (i) shows that over 90% of
NE still remained inhibited by elafin when the inhibitor was
incubated alone or with 200 nM aeruginolysin. A slight
decrease of NE inhibition to 80% was, however, observed
with the highest concentration of enzyme (2000 nM) used in
our experiment after 6 h incubation wFigure 4B (i)x. Western
blot analysis of samples with 200 nM aeruginolysin demon-
strated that elafin was completely cleaved after 1 h into a
unique cleavage product wFigure 4B (ii)x that retained inhib-
itory properties as shown in Figure 4B (i).
Identification of pseudolysin and aeruginolysin
generated cleavage sites
Elafin fragments generated by pseudolysin and aeruginolysin
were separated by reverse phase HPLC (Figure 5) and iden-
tified by electrospray mass spectrometry. HPLC analysis of
elafin incubated with 10 nM pseudolysin resulted in the gen-
eration of three main peaks (Figure 5A, peaks 1, 2 and 3).
As shown in Table 1, product peptides of elafin were iden-
tified in peaks 1 and 2, whereas peak 3 was exclusively
composed of the full-length elafin. A single peptide was
identified in peak 1; it contained residues 26–57. The major
708 N. Guyot et al.
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Figure 2 Effect of Pseudomonas aeruginosa (PAO1)-conditioned
medium on the anti-elastase activity of elafin.
Recombinant elafin was incubated with Tryptic Soy Broth (control)
or PAO1-conditioned medium wpreincubated in the absence or in
presence of the metalloproteinase inhibitors EDTA and phosphor-
amidon (Pa)x for 0, 1, 2 and 6 h and analysed for its inhibitory
activity against neutrophil elastase (NE) by spectrophotometry using
the NE substrate MeOSuc-AAPV-pNA.
Figure 3 Effect of purified Pseudomonas aeruginosa metalloproteases on the integrity of recombinant elafin.
Recombinant elafin (3 mg, 25 mM) was incubated with various concentrations of purified (A) pseudolysin (0–1 mM), (B) staphylolysin
(0–10 mM) and (C) aeruginolysin (0–4 mM) for 2 h at 378C. Incubation products were separated by SDS-PAGE and visualised by Coomassie
Blue staining.
(94%) elafin product detected in peak 2 was identified as
containing residues 1–23. A peptide containing residues
1–24 constituted 5% and one with residues 1–25 was detect-
ed at 0.4%. These results indicate that 10 nM pseudolysin
cleaved the inhibitor between Met25 and Leu26. The use of
a higher concentration of the pseudolysin (100 nM) led to
the elimination of native elafin (peak 3) and an increase in
peaks 1 and 2 (Figure 5A). A HPLC chromatogram of elafin
incubated with 400 nM aeruginolysin also displayed three
major peaks (Figure 5B). Measured masses for each peak are
indicated in Table 2 with the corresponding assigned
sequence. The measured masses of peaks 1 and 3 allowed
their identification as elafin residues 1–6 and 7–57. Peak 2
was identified as the native elafin. These data indicate that
400 nM aeruginolysin cleaved elafin at the Lys6-Gly7 pep-
tide bond within 2 h incubation. Cleavage sites of elafin by
pseudolysin and aeruginolysin are summarised in Figure 5C.
Effect of PAO1-conditioned medium on the
anti-neutrophil elastase activity of normal
bronchoalveolar lavage (BAL) fluid
PAO1-conditioned medium was incubated with bronchoal-
veolar lavage (BAL) fluid from healthy patients to mimic the
first steps of colonisation of the lung by P. aeruginosa. As
shown in Figure 6, normal BAL fluid exhibited anti-NE
activity. The incubation of normal BAL fluid with PAO1-
conditioned medium led to a rapid decrease in the anti-NE
activity of the BAL fluid as 63%, 37% and 17% of inhibition
of NE were detected after 1, 2 and 6 h of incubation, respec-
tively, whereas normal BAL fluid displayed 78% of inhibi-
tion of NE after 6 h. Pretreatment of PAO1-conditioned
medium with the metalloprotease inhibitors EDTA and phos-
phoramidon (a specific inhibitor of pseudolysin) resulted in
the retention of anti-NE activity of the normal BAL fluid to
a similar level of that observed for control: 73% and 82%
of NE still remained inhibited by BAL fluid after 6 h incu-
bation with PAO1-conditioned medium pretreated with phos-
phoramidon and EDTA, respectively.
Effect of aeruginolysin on the transglutaminase-
mediated crosslinking of elafin to fibronectin
In contrast to our findings with pseudolysin, aeruginolysin
cleaved recombinant elafin within its amino terminal extrem-
ity at Lys6-Gly7 and this cleavage did not alter its inhibitory
properties. However, the amino terminal extremity of elafin
contains a transglutaminase substrate motif (AQEPVK) that
could be involved in crosslinking the inhibitor to ECM pro-
teins by transglutamination. We thus hypothesised that the
Effects of Pseudomonas proteases on elafin activities 709
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Figure 4 Effect of purified pseudolysin and aeruginolysin on the inhibitory activity of elafin.
Recombinant elafin was incubated alone (control) or with various concentrations of (A) pseudolysin or (B) aeruginolysin for 0, 1, 2 and
6 h at 378C. Samples were analysed (i) by spectrophotometry for their inhibitory activity toward neutrophil elastase (NE) using the NE
substrate MeOSuc-AAPV-pNA and (ii) by Western blotting under reducing (upper panels) and non-reducing (lower panels) conditions to
confirm elafin cleavage in the presence of pseudolysin and aeruginolysin. Arrows and arrowheads indicate native elafin and cleavage
products of elafin, respectively.
removal of this motif by aeruginolysin could suppress the
transglutaminase-mediated binding of elafin to ECM pro-
teins. Elafin has previously been shown to crosslink a num-
ber of ECM proteins including fibronectin. Therefore, we
investigated the ability of the amino terminal truncated form
of elafin to crosslink fibronectin by transglutamination.
Recombinant elafin was pretreated with increasing concen-
trations of aeruginolysin and then incubated with GM6001.
Samples were then incubated with plasma fibronectin in the
presence or absence of guinea pig liver transglutaminase.
Results were analysed by Western blotting using anti-elafin
antibodies (Figure 7A) and anti-fibronectin antibodies (Fig-
ure 7B). As shown in Figure 7A (lanes 1–6), native recom-
binant elafin had an apparent mass of 7 kDa under
non-reducing conditions. However, in the presence of fibro-
nectin and transglutaminase (lanes 2, 4 and 6), part of the
inhibitor was also detected at high molecular mass
()188 kDa) suggesting that the inhibitor was covalently
crosslinked to fibronectin. Treatment of elafin with 100 nM
aeruginolysin cleaved elafin resulted in the inhibition of its
ability to crosslink to fibronectin by transglutamination (Fig-
ure 7A, lane 8). This effect is due to the truncation of elafin
rather than fibronectin degradation as samples were treated
with GM6001 to suppress metalloproteinase activity (Figure
7B).
Effect of pseudolysin on the antibacterial activity
of elafin
The ability of pseudolysin to inactivate the inhibitory activity
of elafin by cleaving the protease-binding loop prompted us
to investigate the effect of such cleavage on the antibacterial
710 N. Guyot et al.
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Figure 5 HPLC-mass spectrometry analysis of elafin incubated with pseudolysin and aeruginolysin.
Recombinant elafin (3 mg, 25 mM) was incubated with various concentrations of pseudolysin or aeruginolysin for 2 h at 378C. Samples
were then analysed by reverse phase HPLC coupled to electrospray mass spectrometry. (A) HPLC analysis of elafin incubated with 10 nM
(black line) and 100 nM (grey line) pseudolysin. (B) HPLC analysis of elafin incubated alone (grey line) or with 200 nM (black line)
aeruginolysin. (C) Identification of the cleavage sites in elafin. The amino acid sequence of elafin is represented from the amino-terminus
(Ala1) to the carboxy-terminus (Gln57). The lines indicate the position of the disulphide bridges and the asterisk identifies the residue in
P1 position within the protease-binding loop. Arrows highlight the cleavage sites generated by pseudolysin (at Met25-Leu26) and aerugi-
nolysin (at Lys6-Gly7).
activity of elafin (Figure 8). Previous studies have demon-
strated antibacterial activities of elafin against various bac-
teria including P. aeruginosa and were confirmed in our
study by dose-response experiments using recombinant elafin
and P. aeruginosa PAO1. PAO1 survival was diminished as
a function of elafin concentration used (Figure 8A). To
ensure that the observed effect was only due to the recom-
binant elafin, we assessed the purity of the elafin preparation
by SDS-PAGE. As shown in Figure 8B, no contamination
was observed as only one single band corresponding to elafin
was detected at around 7 kDa after silver staining. The anti-
bacterial assay was then performed using elafin treated with
30 and 3000 nM pseudolysin to generate cleaved forms of
elafin. Our results presented in Figure 8C demonstrate that
elafin, even cleaved by 30 and 3000 nM pseudolysin, retained
its antibacterial properties against P. aeruginosa PAO1.
Discussion
Pseudomonas aeruginosa is an opportunistic Gram-negative
bacterium causing severe infections in vulnerable hosts. Such
infections can affect various tissues such as lung, cornea,
skin or urinary tract. In the lung, P. aeruginosa is responsible
for acute respiratory infections common in ventilated and
immunocompromised patients and causes chronic respiratory
Effects of Pseudomonas proteases on elafin activities 711
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Table 1 Monoisotopic mass of elafin fragments gener-
ated by pseudolysin.
Peak Observed Calculated Assignment
mass (Da) mass (Da)
1 3426.53 3426.51 P26–57
2 2392.31 2392.30 P1–23
3 6002.86 6002.88 Full-length P1–57
Elafin fragments obtained with pseudolysin and identified
by HPLC (peaks 1, 2 and 3, Figure 5A) were analysed by
mass spectrometry. The observed and calculated monoiso-
topic masses for the components constituting over 90% of
each peak are represented.
Table 2 Monoisotopic mass of elafin fragments gener-
ated by aeruginolysin.
Peak Observed Calculated Assignment
mass (Da) mass (Da)
1 670.36 670.36 P1–6
2 6002.86 6002.88 Full-length P1–57
3 5350.52 5350.52 P7–57
Elafin fragments obtained with aeruginolysin and identi-
fied by HPLC (peaks 1, 2 and 3, Figure 5B) were analysed
by mass spectrometry. The observed and calculated masses
and assigned sequence for each peak are represented.
Figure 6 Inactivation of the anti-NE activity of normal BAL fluid
by Pseudomonas aeruginosa PAO1-conditioned medium.
Normal BAL fluid was incubated with Tryptic Soy Broth (control)
or PAO1-conditioned medium, preincubated in the absence or pres-
ence of EDTA and phosphoramidon (Pa) for 0, 1, 2 and 6 h and
analysed for its inhibitory activity against neutrophil elastase (NE)
by spectrophotometry using the NE substrate MeOSuc-AAPV-pNA.
infections in patients with cystic fibrosis. The severity of
Pseudomonas infections is due to the ability of the pathogen
to secrete extracellular factors associated with virulence,
including toxins (exotoxin A, exoenzyme S), hemolysins
(phospholipase C, lecithinase) and proteolytic enzymes.
Pseudomonas proteases can cleave and inactivate a variety
of lung proteins with important biological functions and are
thus thought to play a role in promoting bacterial invasion.
To date, one serine protease (arginyl peptidase) and three
metalloproteases (pseudolysin, staphylolysin, aeruginolysin)
have been associated with virulence of P. aeruginosa.
Among these proteases, pseudolysin (Pseudomonas elastase,
LasB) has been demonstrated to cleave and inactivate AAT
and SLPI, two inhibitors of neutrophil serine proteases found
in the lung. We confirmed in our study that both inhibitors
are cleaved by proteases secreted by P. aeruginosa PAO1
following 24 h incubation. Interestingly, we found that only
a combination of inhibitors of metalloproteases (EDTA) and
serine proteases (Pefabloc) prevented this cleavage of SLPI
and AAT. These results demonstrate that, in addition to pseu-
dolysin, a serine protease secreted by P. aeruginosa PAO1 is
able to cleave these inhibitors. We hypothesise that arginyl
peptidase (protease IV) and/or LasD could be involved in
this process. However, there is no evidence to date that Pseu-
domonas serine protease(s) can inactivate SLPI or AAT.
Our study indicates that elafin is also susceptible to pro-
teolytic cleavage by Pseudomonas proteases, as the inhibitor
is rapidly degraded in the presence of the supernatant of P.
aeruginosa PAO1 culture. Additionally, we found that Pseu-
domonas supernatant is able to decrease the anti-NE activity
of elafin. In contrast to SLPI and AAT, we found that only
metalloprotease inhibitors (EDTA, GM6001 and phospho-
ramidon) prevented elafin cleavage. This result demonstrates
that elafin is susceptible to one or more Pseudomonas metal-
loproteases. The observed resistance of elafin to proteolysis
mediated by Pseudomonas serine protease(s) suggests that it
is not as sensitive as SLPI and AAT, or could be explained
by the capacity of elafin to inhibit serine protease(s) secreted
by the pathogenic microorganism. Indeed, a recent study sug-
gests that elafin inhibits growth of P. aeruginosa in complex
media via the inhibition of a serine protease produced by the
pathogen, presumably the arginyl peptidase protease IV
(Bellemare et al., 2008). Identification of the Pseudomonas
metalloprotease(s) involved in the cleavage and inactivation
of elafin was carried out using purified Pseudomonas metal-
loproteases: pseudolysin, staphylolysin (LasA) and aerugi-
nolysin (Pseudomonas alkaline protease, serralysin). Our
study provides evidence that pseudolysin and aeruginolysin,
but not staphylolysin, are able to cleave recombinant elafin.
Although two Pseudomonas metalloproteases were shown to
degrade elafin, functional investigations demonstrate that
these proteases have distinct effects on the functional activ-
ities of elafin.
Elafin is a protein inhibitor belonging to the chelonianin
family, one of the 18 families of canonical inhibitors (Las-
kowski et al., 2000; Krowarsch et al., 2003). The canonical
inhibitors are a group of protein inhibitors characterised by
a conserved protease-binding loop. The inhibitory loop is
convex and matches perfectly with the concave active site
of the target enzyme. The inhibition of proteases by the
canonical inhibitors is reversible and obeys the standard
mechanism of canonical inhibitors well-described elsewhere
(Laskowski et al., 2000; Krowarsch et al., 2003). The crys-
tallised structure of the complex between elafin and porcine
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Figure 7 Effect of purified aeruginolysin on transglutaminase-mediated crosslinking of elafin to fibronectin.
Recombinant elafin (100 ng, 3 mM) was incubated for 2 h at 378C with increasing amounts of aeruginolysin (lanes 1 and 2: no enzyme, 3
and 4: 1 nM, 5 and 6: 10 nM, 7 and 8: 100 nM, 9 and 10: 1000 nM). Samples were treated with GM6001 to inactivate aeruginolysin activity
and incubated for 1 h at 378C with fibronectin in the absence (lanes 1, 3, 5, 7) or presence (lanes 2, 4, 6, 8) of 0.38 mU guinea pig liver
transglutaminase (TGase). Samples were analysed by SDS-PAGE followed by Western blotting using (A) a biotinylated anti-elafin antibody
and (B) an anti-fibronectin antibody. In panel (A) intact and cleaved elafin (respectively denoted elafin and elafin*) are indicated by
arrowheads.
pancreatic elastase (Tsunemi et al., 1996) indicates that seven
residues of the inhibitory loop (Leu20–Leu26) are in contact
with the enzyme and that the scissile bond is located at
Ala24-Met25 also described as P1-P19 peptide bond accord-
ing to the nomenclature of Schechter and Berger (Schechter
and Berger, 1967). In the present study, we report that pseu-
dolysin cleaves elafin within its protease-binding loop yield-
ing two peptides as major products, P1–23 and P26–57. The
key consequence of pseudolysin-mediated cleavage of elafin
is the removal of both P1 and P19 amino acid residues (Ala24
and Met25) from the protease-binding loop. Curiously, the
elafin fragments, 1–23 and 26–57, generated by pseudolysin
were detected by Western blotting under non-reducing con-
ditions but not in the presence of reducing agents. This fea-
ture could be explained at least in part by the weak ability
of the antibody to detect reduced elafin. The gap generated
by the lack of the P1 and P19 residues within the canonical
loop could prevent association with target enzymes and thus
prevent elafin inhibiting NE, as demonstrated in our study.
The role of pseudolysin in the inactivation of elafin and the
pulmonary anti-NE defence is underlined in our study by the
capacity of phosphoramidon, a specific inhibitor of pseudo-
lysin with no effect on staphylolysin and aeruginolysin activ-
ities, to prevent anti-elastase inactivation in normal BAL by
PAO1-conditioned medium. The reason for using normal
BAL in the study was to mimic the initial phases of the lung
infection by P. aeruginosa. However, a severe infection will
lead to a rapid and a massive influx of neutrophils into the
lungs followed by a secretion of large amounts of neutrophil
serine proteases in the airways including the target enzymes
of elafin: NE and Pr3. In this context, a competition can then
occur between pseudolysin and neutrophil serine proteases
for the interaction with elafin. In addition, pseudolysin can
inactivate neutrophil elastase making it difficult to evaluate
the inactivation of elafin by pseudolysin in the presence of
neutrophil elastase (Do¨ring et al., 1985). In contrast to pseu-
dolysin, aeruginolysin does not inactivate elafin. This
enzyme was shown to cleave the inhibitor at Lys6-Gly7. This
peptide bond is located in the amino terminal extremity of
the inhibitor and structural data indicate that the amino ter-
minal region (1–8) of elafin is flexible and is not involved
in the antiprotease function of the inhibitor (Tsunemi et al.,
1996; Francart et al., 1997). As with pseudolysin cleavage
of elafin, the elafin fragment Gly7-Gln57 generated by aeru-
ginolysin was detected by Western blotting under non-reduc-
ing conditions but not in the presence of reducing agents.
Once again, this feature could be explained at least in part
by the weak ability of the antibody to detect reduced elafin.
Moreover, this observation could also suggest that the frag-
ment Ala1-Lys6 contains a major epitope for the antibody.
Similar observations were previously reported with the elafin
fragments Lys6-Gln57 and Ser10-Gln57 generated by neu-
trophil elastase (Guyot et al., 2008).
Several studies have demonstrated that elafin and its pre-
cursor trappin-2 have intrinsic antimicrobial activities against
various pathogens including bacteria (such as P. aeruginosa,
Staphylococcus aureus and Klebsiella pneumoniae) and fun-
gi (Aspergillus fumigatus, Candida albicans). Nevertheless,
the mechanism by which elafin and trappin-2 act as antimi-
crobials remains unclear. It is thought that the cationic nature
of both inhibitors as well as their structure (WAP domain)
can play a key role in this process. Moreover, it has been
found recently that elafin/trappin-2 can use an antimicrobial
mechanism dependent (Bellemare et al., 2008) or independ-
ent (Baranger et al., 2008) of their antiprotease properties. It
seems that the antimicrobial effect against P. aeruginosa and
the mechanism of action of elafin/trappin-2 differ depending
on the bacterial strain used in the studies. In the present
study, we tested the antibacterial properties of elafin against
P. aeruginosa PAO1. Around 30–40% of control PAO1 was
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Figure 8 Effect of purified pseudolysin on the antibacterial activity of recombinant elafin against Pseudomonas aeruginosa PAO1.
(A) Dose-response effect of elafin on P. aeruginosa PAO1 survival. Various concentrations of elafin (0–2.5 mM) were incubated with P.
aeruginosa PAO1 for 2 h. Colonies were counted and the results were expressed as percentage of bacteria survival. Values are means"SEM
(ns5). (B) Purity of recombinant elafin assessed by SDS-PAGE and silver staining. M: molecular mass marker; lane 1: 1 mg elafin; lane
2: 200 ng elafin. (C) Effect of pseudolysin-cleaved elafin on P. aeruginosa PAO1 survival. Recombinant elafin (0 or 41.6 mM) was treated
with increasing concentrations of pseudolysin (0, 30 and 3000 nM) for 2 h and treated with or without GM6001 as indicated in the Figure.
Samples (diluted 41.6 times) were incubated with P. aeruginosa PAO1 for 2 h. Bacterial survival was determined by counting the colony-
forming units. Results are expressed as percentage of PAO1 survival. Values are means"SEM (ns5). One-way analysis of variance was
performed to determine the statistical significance of the effects of elafin and concentrations of pseudolysin on PAO1 survival (*p-0.05;
ns, not significant). Insets represent elafin integrity determined by Western blotting under non-reducing conditions.
recovered after treatment with 1–2.5 mM elafin. These results
are similar to those obtained previously by Simpson et al.
(1999). Interestingly, our data demonstrate that the cleavage
of elafin by pseudolysin within the protease-binding region
did not alter antibacterial properties of elafin against PAO1,
whereas its anti-NE activity was inhibited. These findings
suggest an anti-PAO1 activity independent of its antiprotease
properties for elafin, as previously demonstrated for trappin-
2 (Baranger et al., 2008).
Elafin and its precursor trappin-2 are substrates of trans-
glutaminases (Molhuizen et al., 1993; Nara et al., 1994;
Guyot et al., 2005b). Transglutaminases are enzymes that
catalyse the formation of an isopeptide bond between the
lateral chains of a lysine residue and a glutamine residue. By
this mechanism, trappin-2 and elafin can covalently associate
with structural proteins. In vivo, elafin/trappin-2 was shown
to be covalently crosslinked to components in the tracheal
epithelium that have not yet been identified (Nara et al.,
1994). In the epidermis, elafin and trappin-2 were shown to
associate with a number of structural proteins of the cornified
cell envelope (including keratin-1, loricrin, involucrin and
desmoplakin I/II among others). In vitro, elafin can crosslink
to elastin, fibronectin, collagen, laminin, fibrinogen (Nara et
al., 1994; Guyot et al., 2005b; Muto et al., 2007). The amino
terminal sequence of elafin seems to be important in the
capacity of the inhibitor to crosslink by transglutamination,
as we have shown that the removal of Ala1-Lys6 sequence
by aeruginolysin inhibited crosslinking of elafin to fibronec-
tin following transglutaminase activity. This is in agreement
with recent results demonstrating that elafin fragment trun-
cated at its amino-terminus (Ser10-Gln57) is unable to bind
fibronectin by transglutamination (Guyot et al., 2005b).
Interestingly, elafin crosslinked to fibronectin retains its
inhibitory properties and can protect fibronectin against NE
(Guyot et al., 2005b) suggesting a role for elafin in the pre-
servation of structural proteins against proteolysis mediated
by neutrophil serine proteases. Given that aeruginolysin can
inhibit the covalent binding of elafin to fibronectin in vitro,
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then it is likely that during infection, P. aeruginosa can reg-
ulate elafin crosslinking and subsequent protection against
increased proteolysis mediated by neutrophils.
In conclusion, this study provides evidence that metallo-
proteases secreted by P. aeruginosa can cleave elafin at dif-
ferent sites and specifically alter functions associated with
the inhibitor. Among these proteases, pseudolysin is able to
inactivate the antiprotease properties of elafin. In contrast,
aeruginolysin can potentially perturb the transglutaminase-
mediated crosslinking of elafin to ECM proteins. Therefore,
both proteases could affect the protective role of elafin
against neutrophil-mediated proteolysis in the lung via dif-
ferent mechanisms, shedding further light on the pathogen-
esis of Pseudomonas infections. The inactivation of elafin
and pulmonary anti-elastase defence by P. aeruginosa could
considerably disturb lung epithelial homeostasis. In this
regard, these findings could have pathological importance.
Materials and methods
Materials
Recombinant human elafin was obtained from Proteo Biotech AG
(Kiel, Germany). Biotinylated anti-human elafin antibody and
recombinant SLPI were purchased from R&D Systems (Abingdon,
Oxon, UK). Na-tosyl-L-lysine chloromethyl ketone hydrochloride
(TLCK), leupeptin, Pefabloc, pepstatin A, ethylenediamine-tetraa-
cetic acid (EDTA), guinea pig liver transglutaminase and N-
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (MeOSuc-AAPV-
pNA) were purchased from Sigma-Aldrich (Dublin, Ireland). Pseu-
domonas elastase (EC 3.4.24.26), plasma fibronectin, E-64,
GM6001 and phosphoramidon were purchased from Merck Biosci-
ences (Nottingham, UK). Human neutrophil elastase (NE) (EC
3.4.21.37) was from Elastin Products Company, Inc. (Owensville,
MO, USA). Purified a-1-antitrypsin (AAT) was from Athens
Research (Athens, GA, USA). Horseradish peroxidase (HRP)-con-
jugated streptavidin was purchased from Cambridge BioSciences
Ltd (Cambridge, UK). SuperSignal West Femto Maximum Sensi-
tivity Substrate was purchased from Pierce (Medical Supply Co.,
Dublin, Ireland). Pseudomonas alkaline protease (EC 3.4.24.40) was
from Nagase Biochemicals (Fukuchiyama, Japan). LasA (EC
3.4.24.-) was obtained from Prof. Efrat Kessler (Tel-Aviv University
Sackler University of Medicine, Tel-Hashomar, Israel). All other
reagents were of analytical grade.
Pseudomonas PAO1-conditioned medium
Pseudomonas aeruginosa strain 01 (PAO1) was a gift from R. Han-
cock (University of British Columbia). PAO1-conditioned medium
was prepared by filter-sterilising culture supernatants from 72 h
PAO1 Trypticase Soy Broth cultures.
Incubations and SDS-PAGE analysis
PAO1 conditioned-medium (10 ml) was preincubated for 0.5–1 h
at 378C alone or with the following protease inhibitors: 10 mM
Pefabloc, 0.13 mM TLCK, 0.6 mM leupeptin, 0.4 mM E-64, 0.4 mM
pepstatin A, 13 mM EDTA, 0.5 mM GM6001 or 0.2 mM phospho-
ramidon. Recombinant elafin, SLPI or purified AAT (8.5=10-7 M
each) were mixed with 10 ml of pretreated PAO1-conditioned medi-
um in 30 mM Tris-buffered saline (TBS) to a final volume of 20 ml
for 24 h at 378C. Additionally, recombinant elafin (2.5=10-5 M) was
incubated with various concentrations of purified Pseudomonas pro-
teases for 2 h in 30 mM TBS in a 20 ml final volume at 378C and
analysed by SDS-PAGE. All incubations were stopped by adding
sample treatment buffer with or without reducing agent and boiling
samples for 5 min at 1008C. Samples were separated by Tricine
SDS-PAGE using a 17.5% polyacrylamide gel and proteins were
analysed by staining the gel with Coomassie Blue G or by Western
blotting.
Western blotting
Samples separated by Tricine SDS-PAGE were blotted onto a
0.2 mM nitrocellulose membrane (Sigma-Aldrich). The membrane
was blocked for 1 h at room temperature with 3% bovine serum
albumin (elafin), 0.2% Iblock (SLPI) or 5% milk (AAT) in phos-
phate buffered saline (PBS) containing 0.1% Tween 20. Elafin was
detected by using a biotinylated anti-elafin antibody (R&D Systems,
Abingdon, UK; 1:500 dilution, overnight at 48C) followed by per-
oxidase-conjugated streptavidin (Cambridge BioSciences Ltd, Cam-
bridge, UK; 1:2500 dilution, 20 min at room temperature). SLPI
and AAT were detected by incubating the membrane overnight at
48C with rabbit anti-SLPI (1/1000) and anti-AAT (1/1000) antibod-
ies, respectively, followed by a peroxidase-conjugated anti-rabbit
antibody (1/2000) for 1 h at room temperature. Peroxidase activity
was detected with chemiluminescent substrates (Pierce, Medical
Supply Co., Dublin, Ireland).
HPLC-mass spectrometry analysis
Cleavage of elafin by Pseudomonas proteases was assessed by incu-
bating 3 mg elafin with Pseudomonas elastase or alkaline protease
in 30 mM TBS in 20 ml final volume for 2 h at 378C. Protease
activity was neutralised with 1 ml of 0.1 g/ml EDTA for 30 min at
room temperature. Then, 14 ml of each sample was lyophilised for
analysis when it was reconstituted in 10 ml 6 M guanidine HCl,
100 mM Tris pH 8.5, 1 mM EDTA, and 10 mM dithiothreitol (DTT).
Samples were incubated for 30 min at 378C to ensure the reduction
of disulphide bridges. Then, 1 ml of 10% trifluoroacetic acid was
added to each sample to bring the pH below 3. Samples were then
analysed by reverse phase HPLC coupled to electrospray mass spec-
trometry as described elsewhere (Liu et al., 2006). Spectra were
deconvoluted with Mass Hunter version 2 (Agilent Technologies,
Santa Clara, CA, USA), using peaks whereby heights were 1% or
more of the largest peak.
Neutrophil elastase (NE) activity assays
The effect of Pseudomonas proteases on the anti-NE activity of
elafin was assessed as follows: PAO1-conditioned medium or puri-
fied proteases (pseudolysin, aeruginolysin) were pretreated with or
without protease inhibitors (10 mM EDTA or 0.17 mM phosphora-
midon) for 20 min at 378C in 30 mM TBS (20 ml final volume)
and incubated with recombinant elafin for various times (0, 1, 2 or
6 h) at 378C. The reaction mix was diluted with 0.1 M HEPES,
0.5 M NaCl, pH 7.5 containing 0.1% Brij 35 and EDTA and incu-
bated with NE in a 100 ml volume in such a way that elafin final
concentration was two times higher than NE concentration. The
residual activity of NE was determined spectrophotometrically by
adding 50 ml of 3 mM MeOSuc-AAPV-pNA and by measuring the
absorbance at 405 nm over time at 378C. Inhibition of NE was
expressed as a percentage of the NE present in control samples. The
same method was applied to study the effect of PAO1-conditioned
medium on the anti-NE activity of normal BAL fluid. Then, 2 ml
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of PAO1-conditioned medium and 10 ml of a pooled fraction of
normal BAL fluids (ns5) were used in the initial reaction.
Crosslinking of elafin to fibronectin by
transglutamination
Recombinant elafin (100 ng, 3 mM) was incubated with increasing
concentrations of aeruginolysin (0–100 nM) in PBS for 2 h at 378C.
Aeruginolysin was inactivated by 198 mM GM6001 for 30 min. The
resulting mix was incubated in 200 mM Tris-acetate pH 6 containing
5 mM CaCl2 and 0.1 mM DTT for 1 h at 378C with 5 mg plasma
fibronectin and 0.38 mU guinea pig liver transglutaminase (1 unit
catalyses the formation of 1.0 mM of hydroxamate per minute from
Na-CBZ-glutaminylglycine and hydroxylamine at pH 6.0 at 378C).
The reaction was stopped by adding sample treatment buffer without
reducing agent and by boiling samples for 5 min at 1008C. Samples
were separated by 4–12% Bis-Tris SDS-PAGE (Invitrogen, Bio Sci-
ences Ltd., Dun Laoghaire, Ireland) and analysed by Western blot-
ting using a biotinylated anti-elafin antibody as described above.
Antibacterial assay
A single P. aeruginosa PAO1 colony was grown in 10 ml Tryptic
Soy Broth (Sigma-Aldrich, Dublin, Ireland) at 378C with agitation
(250 rpm). After 4–6 h of growth, the PAO1 culture was centrifuged
(4000 g, 10 min) and the bacterial pellet was washed and resuspen-
ded in PBS. Then, 50 ml of PAO1 diluted 10 000 times was mixed
with 50 ml of recombinant elafin (0–2.5 mM) in PBS. The reaction
mixture was incubated for 2 h at 378C with agitation (250 rpm).
Then, 10 ml of various serial dilutions of the reaction mixtures were
spread on Tryptic Soy Agar plates (Sigma-Aldrich) and incubated
overnight at 378C. The colonies were counted and expressed as
PAO1 survival compared with PAO1 alone as control (100%). To
study the effect of pseudolysin on the antibacterial activity of elafin,
the inhibitor was treated as follows: 41.6 mM recombinant elafin
was incubated with increasing concentrations of pseudolysin (0, 30
and 3000 nM) in PBS for 2 h at 378C and treated with 60 mM
GM6001 to stop the reaction. Controls were also carried out using
pseudolysin alone and PBS alone without GM6001 in the same
conditions. The reaction mixtures were diluted 41.6-fold in 100 ml
PBS (final elafin concentration: 0 or 1 mM) containing PAO1 as
described above.
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